CoChat
Sign Up
Cited by 118Blood properties and coagulationLipoproteins and Cardiovascular HealthCardiovascular Health and Risk Factors

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Fibrinogen Is a Predictor of Mortality in Coronary Heart Disease Patients

Open access
Benderly, Michal, Graff, Eran, Reicher-Reiss, Henrietta, Behar, Solomon, Brunner, Daniel, Goldbourt, Uri·1996·Arteriosclerosis, Thrombosis, and Vascular Biology
DOI 10.1161/01.atv.16.3.351
Open this paper in CoChat — free accountOpen PDF

Abstract

Abstract Results of epidemiological studies have indicated that fibrinogen is an important primary cardiovascular risk factor. The role of fibrinogen as a predictor of mortality in coronary heart disease (CHD) patients is unclear. We investigated the association between fibrinogen and mortality in a large cohort of CHD patients screened for participation in a secondary prevention clinical trial. Of the total investigated, 3092 men who were not included in the trial and for whom vital status was known were followed up for a mean period of 3.2 years. In 54.4% of the 111 men who died, mortality was attributed to CHD. Mean baseline plasma fibrinogen levels were 29.4 mg/dL higher in patients who died than in the survivors. All-cause and CHD mortality rates increased with increasing fibrinogen levels. This relationship was also demonstrated within categories of the primary variables predicting mortality in these patients. The contribution of fibrinogen to CHD and all-cause mortality was assessed by multivariate analysis adjusting for age, CHD severity, and comorbidity. Risks of CHD and all-cause mortality for patients in the highest fibrinogen tertile were 1.67 and 1.75, respectively, relative to patients in the lowest tertile, and an increase of about 1 SD of plasma fibrinogen level (75 mg/dL) was found to increase risk of CHD and all-cause mortality by 29% and 31%, respectively. These results indicate clearly that fibrinogen level is associated with significantly increased mortality in CHD patients. Implementation of a standardized measuring method is required to allow assessment of risk in CHD patients on the basis of fibrinogen levels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.atv.16.3.351

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 6

  1. 1985, J R Coll Gen Pract, 35, 564
  2. 10.1161/atv91.14.1.8274478 · DOI
  3. SAS/STAT User’s Guide Version 6 . 4th ed. Cary NC: SAS Institute Inc; 1987;1:943 and 1987;2:620.
  4. SAS/STAT software: changes and enhancements release 6.07. Cary NC: SAS Institute Inc; 1992:620. SAS technical report P-229.
  5. 1996, J Clin Epidemiol, 48, 757
  6. 1990, J Clin Epidemiol, 16, 83

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Benderly, M., Graff, E., Reicher-Reiss, H., Behar, S., Brunner, D., & Goldbourt, U.
Affiliations
Sheba Medical Center (IL)
ORCID
Benderly, Michal
Venue
Arteriosclerosis, Thrombosis, and Vascular Biology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
1996-03
Volume
16
Issue
3
Pages
351-356
ISSN
  • 1079-5642 (ISSN-L)
  • 1524-4636
DOI
10.1161/01.atv.16.3.351
OpenAlex
W2143889573
Cited by
118
References
18
Citations by year
2023: 1 · 2021: 2 · 2020: 3 · 2019: 4 · 2016: 2 · 2015: 2 · 2014: 5 · 2013: 1 · 2012: 4
FWCI
12.51
Type
journal article
Language
en
Open access
Locations
  • Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Blood properties and coagulation
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
Keywords
fibrinogen, coronary artery disease, mortality prediction, cardiovascular risk factors, all-cause mortality, secondary prevention, plasma fibrinogen levels, risk stratification
MeSH terms
Aged, Coronary Disease, Fibrinogen, Follow-Up Studies, Humans, Male, Middle Aged, Smoking

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review